PDF(Pubmed)
Abstract：
UNASSIGNED: To investigate the prognostic value of local therapy (LT) in cN1M0 prostate cancer (PCa).
UNASSIGNED: Patients diagnosed with cN1M0 PCa were extracted from the surveillance, epidemiology, and end results (SEER) database. Kaplan-Meier (KM) curve was used to compare the survival outcomes between patients treated with and without LT. Further, among patients receiving LT, KM analysis was also applied to investigate the survival differences in patients with radical prostatectomy (RP) and radiation therapy (RT). Propensity score matching (PSM) analysis was performed to balance the basic characteristics of patients in each group and make it comparable when exploring the survival impact of different treatment types. Finally, uni- and multivariable Cox proportional-hazards models were utilized to identify independent prognostic factors associated with overall survival (OS) and cancer-specific survival (CSS) in this population.
UNASSIGNED: Patients treated with LT had significantly better OS (P<0.0001) and CSS (P<0.0001) than those without LT, as well as in most subgroups, except for non-White patients, or those with ISUP grade group 1 or T3 stage. Notably, patients receiving RP also had significantly better OS (P=0.00012) and CSS (P=0.0045) than those treated with RT alone, especially in those aged ≥75 years old, prostate-specific antigen (PSA) 10-20 ng/mL, ISUP grade 1-3 or non-white patients. Finally, clinical T stage, ISUP grade group and the administration of LT were identified to be independent prognostic factors for OS and CSS among cN1M0 PCa patients.
UNASSIGNED: The cN1M0 PCa patients treated with LT were associated with significantly better survival. Among patients receiving LT, the combination of RP and PLND could lead to a better prognosis compared to RT alone in most subgroups. An individualized treatment strategy is warranted to be developed after weighing the benefits and risks of treatment.
UNASSIGNED: Patients diagnosed with cN1M0 PCa were extracted from the surveillance, epidemiology, and end results (SEER) database. Kaplan-Meier (KM) curve was used to compare the survival outcomes between patients treated with and without LT. Further, among patients receiving LT, KM analysis was also applied to investigate the survival differences in patients with radical prostatectomy (RP) and radiation therapy (RT). Propensity score matching (PSM) analysis was performed to balance the basic characteristics of patients in each group and make it comparable when exploring the survival impact of different treatment types. Finally, uni- and multivariable Cox proportional-hazards models were utilized to identify independent prognostic factors associated with overall survival (OS) and cancer-specific survival (CSS) in this population.
UNASSIGNED: Patients treated with LT had significantly better OS (P<0.0001) and CSS (P<0.0001) than those without LT, as well as in most subgroups, except for non-White patients, or those with ISUP grade group 1 or T3 stage. Notably, patients receiving RP also had significantly better OS (P=0.00012) and CSS (P=0.0045) than those treated with RT alone, especially in those aged ≥75 years old, prostate-specific antigen (PSA) 10-20 ng/mL, ISUP grade 1-3 or non-white patients. Finally, clinical T stage, ISUP grade group and the administration of LT were identified to be independent prognostic factors for OS and CSS among cN1M0 PCa patients.
UNASSIGNED: The cN1M0 PCa patients treated with LT were associated with significantly better survival. Among patients receiving LT, the combination of RP and PLND could lead to a better prognosis compared to RT alone in most subgroups. An individualized treatment strategy is warranted to be developed after weighing the benefits and risks of treatment.
摘要：
未经批准：探讨cN1M0前列腺癌（PCa）局部治疗（LT）的预后价值。
未经证实：从监测中提取诊断为cN1M0PCa的患者，流行病学,和最终结果(SEER)数据库。使用Kaplan-Meier（KM）曲线比较接受和未接受LT治疗的患者的生存结果。Further,在接受LT的患者中，KM分析还用于研究根治性前列腺切除术（RP）和放射治疗（RT）患者的生存差异。进行倾向评分匹配（PSM）分析，以平衡各组患者的基本特征，并在探索不同治疗类型的生存影响时具有可比性。最后,在该人群中,采用单变量和多变量Cox比例风险模型来确定与总生存期(OS)和癌症特异性生存期(CSS)相关的独立预后因素.
UNASSIGNED：接受LT治疗的患者的OS（P<0.0001）和CSS（P<0.0001）明显优于未接受LT治疗的患者，以及在大多数子群中，除了非白人患者,或那些与ISUP等级组1或T3阶段。值得注意的是,接受RP治疗的患者的OS（P=0.00012）和CSS（P=0.0045）也明显优于单纯接受RT治疗的患者，尤其是在年龄≥75岁的人群中，前列腺特异性抗原（PSA）10-20ng/mL，ISUP1-3级或非白人患者。最后,临床T分期,在cN1M0PCa患者中，ISUP分级组和LT的给药被确定为OS和CSS的独立预后因素。
UNASSIGNED：接受LT治疗的cN1M0PCa患者的生存率显著提高。在接受LT的患者中，在大多数亚组中,与单纯RT相比,RP和PLND联合治疗可导致更好的预后.在权衡治疗的益处和风险后，有必要制定个性化的治疗策略。
未经证实：从监测中提取诊断为cN1M0PCa的患者，流行病学,和最终结果(SEER)数据库。使用Kaplan-Meier（KM）曲线比较接受和未接受LT治疗的患者的生存结果。Further,在接受LT的患者中，KM分析还用于研究根治性前列腺切除术（RP）和放射治疗（RT）患者的生存差异。进行倾向评分匹配（PSM）分析，以平衡各组患者的基本特征，并在探索不同治疗类型的生存影响时具有可比性。最后,在该人群中,采用单变量和多变量Cox比例风险模型来确定与总生存期(OS)和癌症特异性生存期(CSS)相关的独立预后因素.
UNASSIGNED：接受LT治疗的患者的OS（P<0.0001）和CSS（P<0.0001）明显优于未接受LT治疗的患者，以及在大多数子群中，除了非白人患者,或那些与ISUP等级组1或T3阶段。值得注意的是,接受RP治疗的患者的OS（P=0.00012）和CSS（P=0.0045）也明显优于单纯接受RT治疗的患者，尤其是在年龄≥75岁的人群中，前列腺特异性抗原（PSA）10-20ng/mL，ISUP1-3级或非白人患者。最后,临床T分期,在cN1M0PCa患者中，ISUP分级组和LT的给药被确定为OS和CSS的独立预后因素。
UNASSIGNED：接受LT治疗的cN1M0PCa患者的生存率显著提高。在接受LT的患者中，在大多数亚组中,与单纯RT相比,RP和PLND联合治疗可导致更好的预后.在权衡治疗的益处和风险后，有必要制定个性化的治疗策略。
